ArthroCare Corporation (OP:ARTC)
21.80
0.25 (1.13%)
| ArthroCare Corporation (OP:ARTC) Delayed : |
| Previous Close |
$22.05 |
|
52 Week High |
$22.40 |
 |
| Open |
$21.55 |
|
52 Week Low |
$2.89 |
| Day High |
$22.00 |
|
P/E |
N/A |
| Day Low |
$21.00 |
|
EPS |
$0.00 |
| Volume |
410,998 |
|
|
|
| More ARTC Info:
Chart
SEC Filings
Profile
Historical
Options
|
View All ReportsStreetInsider.com Reports on ARTC
-
Aug 18, 2009 10:57 AM
Canaccord Adams Upgrades ArthroCare (ARTC) to Buy; Positive on Equity Investment
-
Feb 18, 2009 09:38 AM
ArthroCare (ARTC) Announces Investigations by SEC and US Attorney Offices; CEO Departure and Management Changes
-
Jan 16, 2009 03:29 PM
ArthroCare (ARTC) Obtains a Waiver of Default under Its Credit Agreement
-
Jan 16, 2009 01:18 PM
Unusual 11 Mid-Day Movers 1/16: TRA, AVD, FHN, PSD Higher; RDEN, TONE, BCS, AIB Lower
-
Jan 16, 2009 10:13 AM
ArthroCare (ARTC) Lower After Moving To the Pinks
View All Reports
StreetInsider Reports on ARTC by Category
-
Jul 27, 2009 05:13 AM
Health Care Stocks Anticipate Weak Reform Bill, If Any
-
May 18, 2009 04:31 AM
45 Cheap Repurchasers of Stock
-
Dec 30, 2008 04:57 AM
3 Top and Bottom Market Sectors for This Week
-
Dec 22, 2008 03:48 PM
The 52-Week Low Club (MNI)(MWE)(ARTC)(TXCC)
-
Dec 19, 2008 03:01 PM
52-Week Low Club (ARTC, CORL, GEOY, HPGP, HLND, HRC, PDLI, SNN, TTWO)
View All Blogs
Comments on ARTC
No comments are currently available.
on Dec 19, 2008
at 01:26 PM GM Management I cannot believe Rick Wagoner described him and his team of executives as the best management team in the country. Is his ego big or what? Shares went from $64 when he took over as CEO to less than $5 today. That to me does not sound like good management. Also, what is with all the men. Women are the primary buyer of new cars. Why are they still living in the 1950's? Statistics show that companies that have a more diverse workforce are 65% more productive than companies without diversity. Maybe that is GM's main problem. Overpaid men that participate in groupthink with no fresh ideas or perspectives.
Article: Morning Movers 12/19: ArthroCare (ARTC) Smashed On Restatement Expansion/CFO Resignation; GM Up On Govt Loan
on Sep 24, 2008
at 11:00 PM RBC Signals AMED to Outperform Add RBC to Oppenheimer, Wachovia, and BB&T being bullish on Amedisys; see http://www.marketintelligencecenter.com/articles/662272. Who thinks that Andrew Left of Citron is more knowledgeable than all of these RESPECTED players?
Article: Citron Research Raises The Caution Flag On Amedisys (AMED)
on Sep 24, 2008
at 10:36 PM Tales from the Crypt With the practice of shorting stock indefinitely suspended in the U.S. -- with it possibly becoming illegal under the Bush economic bail out, this may spell the death knell for Citron Research. Shorting stock appears to be a core business strategy employed by the principals of Citron. If what Anonymous said is true about these same principals allegedly shorting Amedisys stock before issuing their "spurious" report, then it must be discounted. Citron may have dug up legitmate dirt on some companies in past, but they also damaged some good ones -- maliciously or not. Bottom line: Take Citron with a grain of salt.
Article: Citron Research Raises The Caution Flag On Amedisys (AMED)
on Sep 22, 2008
at 04:23 PM Here's the 'Secret Sauce' Alluded to in the spurious Citron report... http://www.streetinsider.com/Insiders+Blog/Amedisys+Recognized+among+Top+50+Business+Innovating+Companies+by+InformationWeek+Magazine/4008306.html. Principals at Citron allegedly shorted Amedisys stock before issuing the scathing report. Oppenheimer, Wachovia, and BB&T, et al. weren't fooled. Citron is TOTALLY debunked!
Article: Citron Research Raises The Caution Flag On Amedisys (AMED)
on Sep 22, 2008
at 04:18 PM Here's the Alluded to the the spurious Citron report... http://www.amedisys.com/press_release.cfm?do=view&ID=172. Principals at Citron allegedly shorted Amedisys stock before the scathing report. Oppenheimer, Wachovia, BB&T, et al. weren't fooled. Citron is totally debunked.
Article: Citron Research Raises The Caution Flag On Amedisys (AMED)